(Q46131525)

19 December 2017

title

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register (English)

1 reference

19 December 2017

main subject

TNF

0 references

author

Katerina Chatzidionysiou

1

object named as

Katerina Chatzidionysiou

0 references

Ronald van Vollenhoven

5

object named as

Ronald van Vollenhoven

1 reference

19 December 2017

Johan Askling

2

1 reference

19 December 2017

Jonas Eriksson

3

1 reference

19 December 2017

Lars Erik Kristensen

4

1 reference

19 December 2017

ARTIS group

6

1 reference

19 December 2017

language of work or name

English

0 references

publication date

15 January 2014

1 reference

19 December 2017

Annals of the Rheumatic Diseases

published in

1 reference

19 December 2017

volume

74

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

page(s)

890-896

1 reference

19 December 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Ten years with biologics: to whom do data on effectiveness and safety apply?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Swedish registers to examine drug safety and clinical issues in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Chronic inflammation caused by lymphotoxin is lymphoid neogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204714

10.1136/ANNRHEUMDIS-2013-204714

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017